Prior to joining Amgen in 2002, Bill was a Scientific Director and Project Leader in the Vascular Biology Department at Immunex where he worked in various positions of increasing responsibility within research and development for 14 years (Cellular Immunology, Tumor Immunology and Immunobiology). Bill was involved with preclinical work that led, in part, to the development of Eternacept. During the 12 years Bill was at Amgen, he progressed to become an Executive Director at the Amgen Washington site where he was originally an investigator in the Hematology-Oncology Therapeutic area focusing on target discovery/validation, therapeutic discovery and preclinical development of targeted biotherapeutics including receptor-Fcs, effector function-enhanced monoclonal antibodies, blocking antibodies, anti-CD3 bispecifics and antibody drug conjugates-ADC. As a scientific leader, Bill fostered and managed innovation and moved to the newly formed Therapeutic Innovation Unit (TIU) at Amgen where he directed a group of 19. In the TIU, Bill and his teams developed strategic platforms that offered biological innovation and created novel biological insight into diseases across multiple therapeutic areas/modalities, including cancer immunotherapy, general oncology (targeted therapeutics), iPSC (cyno, human) generation, and cyno autologous tumor model development for pharmacological evaluation of biotherapeutics. Bill was the lead or co-lead of multiple biotherapeutic programs from target discovery and validation into Phase 1. Bill subsequently co-founded Sound Biologics in 2015, where he served as the executive vice president of research and development and drove the biology and IND-enabling/IND filing activities for its lead programs. The company focused on its unique MabPair antibody platform development and on drug discovery and clinical development of MabPairs directed against Oncology and Immuno-Oncology-related targets. Its two lead MabPair, programs, a dual-function ICI, and a targeted B cell lymphoma therapy are currently in Phase 1/2 of clinical development. Bill’s major research interests include growth factor/ growth factor receptors, transplantation.immunobiology, T cell function/adaptive immunity, immunotherapy, immunooncology and cancer biology. Bill has developed multiple preclinical in vivo pharmacology disease models in transplantation, angiogenesis and cancer and has enjoyed developing targeted biological anti-tumor therapies including antibody drug conjugates. Bill has an ongoing interest in translational medicine including the identification and development of biomarkers and building evidence for therapeutic biological impact in patients during the Phase 1 and the E2L transition. Bill is passionate about delivering impactful medicines to cancer patients and other patients with serious illness. Bill is a named inventor on over 50 issued US patents, multiple European/ROW patents and multiple pending applications. He is the author or co-author of more than 110 peer-reviewed publications. Bill received his Ph.D. in Biochemistry and Molecular Biology from the Department of Biochemistry and Cell Biology at Rice University. He did his post-doctoral work at Rice University/UTHSC.